Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Niranjan J Sathianathen, Philipp Dahm, Sarah Jane Brown, Makinna Oestreich, Shilpa Gupta, Badrinath R Konety, Frank Kunath

Research output: Contribution to journalArticlepeer-review

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of early abiraterone acetate in combination with androgen deprivation therapy for newly diagnosed metastatic hormone-sensitive prostate cancer.

Original languageEnglish (US)
Article numberCD013245
JournalCochrane Database of Systematic Reviews
Volume2019
Issue number1
DOIs
StatePublished - Jan 24 2019

Bibliographical note

Publisher Copyright:
© 2019 The Cochrane Collaboration.

Fingerprint Dive into the research topics of 'Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer'. Together they form a unique fingerprint.

Cite this